ALBERT LABS INTL. CORP. Market Cap ($372.07K)
Market Cap & Net Worth: ALBERT LABS INTL. CORP. (VB50)
ALBERT LABS INTL. CORP. market cap. ALBERT LABS INTL. CORP. (F:VB50) has a market capitalization of $372.07K (€318.25K) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #31179 globally and #2754 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALBERT LABS INTL. CORP.'s stock price €0.01 by its total outstanding shares 74413267 (74.41 Million). Also see ALBERT LABS INTL. CORP. (VB50) cash flow conversion for how efficiently the company converts equity into cash flow.
ALBERT LABS INTL. CORP. Market Cap History (2022–2026)
ALBERT LABS INTL. CORP. market cap history from 2022 to 2026. Data shows change from $2.00 Million to $434.98K (-49.39% CAGR). Check ALBERT LABS INTL. CORP. stock quote for real-time trading data and today's change.
ALBERT LABS INTL. CORP. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALBERT LABS INTL. CORP.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is ALBERT LABS INTL. CORP. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VB50 by Market Capitalization
Companies near ALBERT LABS INTL. CORP. in the global market cap rankings as of November 3, 2026. Also see VB50 asset base for a full breakdown of the balance sheet.
Key companies related to ALBERT LABS INTL. CORP. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of ALBERT LABS INTL. CORP. (2022–2026)
Market capitalization of ALBERT LABS INTL. CORP. from 2022 to today. Between 2022 and today, ALBERT LABS INTL. CORP.'s market cap moved from $2.00 Million to $ 434.98K, with a yearly change of -49.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €434.98K | 0.00% |
| 2025 | €434.98K | 0.00% |
| 2024 | €434.98K | +25.00% |
| 2023 | €347.99K | -82.61% |
| 2022 | €2.00 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of ALBERT LABS INTL. CORP. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $372.07K USD |
| MoneyControl | $372.07K USD |
| MarketWatch | $372.07K USD |
| marketcap.company | $372.07K USD |
| Reuters | $372.07K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.